Company:  SINOVAC BIOTECH LTD (SVA)
Form Type:  20-F
Filing Date:  6/30/2004 
CIK:  0001084201 
Address:  NO. 39 SHANGDI XI ROAD
HAIDIAN DISTRICT
 
City, State, Zip:  BEIJING,  100085 
Telephone:  86-10-82890088 
Fiscal Year:  12/31 
Description of Business
Our legal and commercial name is Sinovac Biotech Ltd. Our principal executive offices are located at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, PRC. Our telephone number at this address is +86-10-5693-1800. Our registered address is located at the office of APN Corporate and Management Services Limited, Unit #4 Bryson's Complex, Friars Hill Road, St. John's, Antigua. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. We are a holding company and conduct our business through our 73.09% majority-owned subsidiary Sinovac Beijing, our 59.24% majority-owned subsidiary Sinovac LS, our 68% majority-owned subsidiary Sinovac Dalian, and our wholly owned subsidiaries Sinovac Biomed, Sinovac Hong Kong and Sinovac Biotech (Singapore) Pte. Ltd. ("Sinovac Singapore").
Register and access this filing in:     
  FORM 20-F
    PART I
      ITEM 3 - KEY INFORMATION ...
      ITEM 5 - OPERATING AND FINANCIAL REVIEW AND PROSPECTS ...
      ITEM 6 - DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES ...
      ITEM 7 - MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS ...
      ITEM 8 - FINANCIAL INFORMATION ...
      ITEM 9 - THE OFFERING AND LISTING ...
      ITEM 10 - ADDITIONAL INFORMATION ...
      ITEM 11 - QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT
      ITEM 12 - DESCRIPTION OF SECURITIES OTHER THAN EQUITY
    EXHIBIT INDEX ...
    PART 1
      ITEM 1 - IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
      ITEM 2 - OFFER STATISTICS AND EXPECTED TIMETABLE
        Legal Proceedings
        Liquidity and Capital Resources
        BENEFICIAL OWNERS
        COMPENSATION TABLE
        OPTIONS
        BENEFICIAL OWNERS
      ITEM 8 - FINANCIAL INFORMATION
    PART II
      ITEM 13 - DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
      ITEM 14 - MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY ...
      ITEM 17 - FINANCIAL STATEMENTS
      ITEM 18 - FINANCIAL STATEMENTS
      ITEM 19 - EXHIBITS
        Report of Independent Registered Public Accounting
        Notes to Consolidated Financial Statements
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
          BALANCE SHEET
          STOCKHOLDERS EQUITY
          INCOME STATEMENT
          CASH FLOW
    SIGNATURES
  EXHIBIT 3.1
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 10.4
  EXHIBIT 10.5
  EXHIBIT 10.6
  EXHIBIT 10.7
  EXHIBIT 31.1
    Certification of Disclosure in Sinovac Biotech Ltd.'s
  EXHIBIT 31.2
    Certification of Disclosure in Sinovac Biotech Ltd.'s
  EXHIBIT 32.1
    Certification of Weidong Yin pursuant to Section 906
  EXHIBIT 32.2
    Certification of Lily Wang pursuant to Section 906


EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.